Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Is the BNT162b2 COVID-19 vaccination during pregnancy associated with adverse neonatal outcomes?
Bottom line
Administering the BNT162b2 COVID-19 vaccine during pregnancy is not associated with adverse neonatal outcomes. 1b
Reference
Study design: Cohort (prospective)
Funding: Unknown/not stated
Setting: Population-based
Synopsis
These authors identified a cohort of 24,288 singleton births in Israel from March 1, 2021, through September 31, 2021. A total of 16,697 of the newborns were exposed in utero to the Pfizer-BioNTech COVID vaccine. The authors used propensity scores to adjust for maternal age, timing of conception, parity, socioeconomic status, population subgroup, and maternal influenza immunization status. They had less than 6 months of follow-up on the infants. The authors identified no difference in the rate of preterm births (relative risk [RR] = 0.95; 95% CI 0.83 - 1.10), rate of small for gestational age (RR = 0.97; 0.87 - 1.08), or neonatal hospitalizations (RR = 0.99; 0.88 - 1.12). While congenital anomalies were less frequent in the infants exposed to the vaccine, the absolute number of infants with anomalies was low (RR = 0.69; 0.44 - 1.04). Finally, receipt of the vaccine was associated with a lower risk of delivery before 32 weeks' (RR 0.45; 0.29 - 0.70) and very low birth weight (< 1500 grams; RR 0.41; 0.26 - 0.65). Although encouraging, the data are still inadequate to identify rare events.
Reviewer
Henry C. Barry, MD, MS
Professor
Michigan State University
East Lansing, MI
Comments
Vaccination in pregnancy
There was no comment on how many of those pregnant ladies got Covid in the pregnancy and no comparison of pregnancy out comes in terms of those that had Covid and those that did not
Premature
Isn’t this a bit premature of a conclusion?
covid vaccination in pregnancy
no adverse neonatal outcomes